BRD2 and neoplasm: Category 1: lymph node positive primary tumours (IDC+) versus matched normal adjacent tissue (IDC+ vs NAT+), category 2: lymph node negative primary tumours (IDC-) versus matched normal adjacent tissue (IDC− vs NAT−), and category 3: lymph node metastases versus matched normal adjacent tissue (LNmet vs NAT+) (Fig. 3).